An update on patient reported outcomes in type 2 inflammation airway disease
Research output: Contribution to journal › Review › Research › peer-review
Standard
An update on patient reported outcomes in type 2 inflammation airway disease. / Pedersen, Christian Korsgaard; Haase, Christiane; Aanaes, Kasper; Von Buchwald, Christian; Backer, Vibeke.
In: Current Opinion in Allergy and Clinical Immunology, Vol. 23, No. 1, 2023, p. 1-8.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - An update on patient reported outcomes in type 2 inflammation airway disease
AU - Pedersen, Christian Korsgaard
AU - Haase, Christiane
AU - Aanaes, Kasper
AU - Von Buchwald, Christian
AU - Backer, Vibeke
N1 - Publisher Copyright: © 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Purpose of reviewPatient reported outcome measures (PROMs) play an important role in assessing so-called global airway disease caused by type-2 inflammation, not only in terms of patients' perspective on symptoms and treatment/side-effect, but they can also serve as a measure of disease control, and not least as an indicator of possible coexisting comorbidity otherwise unrecognized. The objective of this review was to investigate any newly developed PROMs for global airway disease and to give an overview of the most commonly used PROMs in the management of global airway disease.Recent findingsThe Standard Tests for Asthma, Allergic Rhinitis and Rhinosinusitis (STARR-15) is a recently developed PROM aimed to raise clinicians' awareness of coexisting type-2 inflammation disease. Strengths of the STARR-15 is that is quick and symptom-centered, i.e. items are not specifically aimed at a disease the patients might not be aware they have. The STARR-15 has, however, not yet been validated, so details of responsiveness and reproducibility are yet to be determined.SummaryPROMs are a quick and cheap way to assess patient perspectives in global airway disease, and can play an important role in unveiling otherwise overlooked co-existing double disease.
AB - Purpose of reviewPatient reported outcome measures (PROMs) play an important role in assessing so-called global airway disease caused by type-2 inflammation, not only in terms of patients' perspective on symptoms and treatment/side-effect, but they can also serve as a measure of disease control, and not least as an indicator of possible coexisting comorbidity otherwise unrecognized. The objective of this review was to investigate any newly developed PROMs for global airway disease and to give an overview of the most commonly used PROMs in the management of global airway disease.Recent findingsThe Standard Tests for Asthma, Allergic Rhinitis and Rhinosinusitis (STARR-15) is a recently developed PROM aimed to raise clinicians' awareness of coexisting type-2 inflammation disease. Strengths of the STARR-15 is that is quick and symptom-centered, i.e. items are not specifically aimed at a disease the patients might not be aware they have. The STARR-15 has, however, not yet been validated, so details of responsiveness and reproducibility are yet to be determined.SummaryPROMs are a quick and cheap way to assess patient perspectives in global airway disease, and can play an important role in unveiling otherwise overlooked co-existing double disease.
KW - global airways disease
KW - Health-related quality of life
KW - patient reported outcome measure
KW - type 2 inflammation
U2 - 10.1097/ACI.0000000000000873
DO - 10.1097/ACI.0000000000000873
M3 - Review
C2 - 36378110
AN - SCOPUS:85144588870
VL - 23
SP - 1
EP - 8
JO - Current Opinion in Allergy and Clinical Immunology
JF - Current Opinion in Allergy and Clinical Immunology
SN - 1528-4050
IS - 1
ER -
ID: 363674613